Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (NGR018)
This study is currently recruiting participants.
Verified January 2013 by MolMed S.p.A.
Study NCT01358071   Information provided by MolMed S.p.A.

First Received on May 19, 2011.   Last Updated on January 28, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ovarian Cancer
Additional conditions recognized in this trial
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Interventions listed in this trial
NGR-hTNF
Pegylated liposomal doxorubicin
Doxorubicin
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
MolMed S.p.A.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services